Acylated phospholipid drugs

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:

• or pharmaceutically acceptable salts thereof and a pharmaceutical carrier therefor wherein
• R is a naturally occurring polar head group characteristic of a glycerophospholipid isolated from endogenous sources;
• R1 and R2 are hydrogen and E1 and E2 are independently heteroatom hydrocarbyl group having 3-25 carbon atoms, wherein at least one of the carbon atoms in the principal chain is replaced by S or O, wherein said substitution does not occur on the α-carbon to the acyl group or on the omega carbon.

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula:

• or pharmaceutically acceptable salts thereof and a pharmaceutical carrier therefor wherein R is CH2CH2NR8R9
• R1 and R2 are independently hydrogen or an alkyl fatty acid acyl group having 4-26 carbon atoms and E1 and E2 are independently heteroatom hydrocarbyl group having 3-25 carbon atoms, wherein one of the carbon atoms in the principal chain is replaced by O or S, and said substitution does not occur on the α-carbon to the acyl group or on the omega carbon and R8 and R9 are independently hydrogen or lower alkyl.

A pharmaceutical composition comprising a pharmaceutically effective amount of compound of the formula:

• or pharmaceutically acceptable salts thereof and a pharmaceutical carrier therefor wherein
• R is a naturally occurring polar head group characteristic of a glycerophospholipid isolated from endogenous sources, E1 and E2 are the same and are heteroatom hydrocarbyl group having 3-25 carbon atoms which may be straight chained or branched wherein one of the carbon atoms in the principal chain is replaced by O or S, said substitution does not occur on the α-carbon to the acyl group or on the omega carbon.

AC1 or the D or L stereoisomer thereof.

AC2 or the D or L stereoisomer thereof.

1-(12 methoxy dodecanoyl)-sn-3-glycerophosphatidyl choline or the D or L stereoisomers thereof.

A compound of the formula which is:

• or pharmaceutically acceptable salts thereof wherein
• E1 is myristoyl or 12-methoxydodecanoyl and
• E2 is 12-methoxydodecanyl.

A method for the inhibition of protein myristoylation in an animal in need thereof comprising administering to said animal an effective amount of a compound according to any one of claims 11-14, 32-36 or 65-76.

A method for the inhibition of protein myristoylation in an animal in need thereof comprising administering to said animal a protein myristoylating inhibiting effective amount of a compound of the formula:

• wherein
• R is a naturally occurring polar head group characteristic of a glycerophospholipid isolated from endogenous sources;
• R1 and R2 are independently hydrogen or an alkyl fatty acid acyl group having 4-26 carbon atoms, and E1 and E2 are independently a heteroatom hydrocarbyl group having 3-25 carbon atoms, wherein at least one of the carbon atoms in the principal chain is replaced by O or S, and wherein such substitution does not occur on the α-carbon to the acyl group or on the omega carbon.

A method for the inhibition of retroviral proliferation in an animal in need thereof comprising administering to said animal a retroviral proliferation inhibiting amount of a compound of the formula

• wherein
• R is a naturally occurring polar head group characteristic of a glycerophospholipid isolated from endogenous sources;
• R1 and R2 are independently hydrogen or an alkyl fatty acid acyl group having 4-26 carbon atoms, and E1 and E2 are independently a heteroatom hydrocarbyl group having 3-25 carbon atoms, wherein at least one of the carbon atoms in the principal chain is replaced by O or S and such substitution does not occur on the α-carbon to the acyl group or on the omega carbon.